GleamWall
中文EN

FENC FENNEC PHARMACEUTICALS INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1211583 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY71.1%
TTM net income YoY129.2%
TTM EPS YoY111.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin5.6%
Net margin3.1%
FCF margin—
EBITDA margin—

Returns

ROE9.1%
ROA3.1%
ROIC (approx.)—
Asset turnover1.00x

Leverage & solvency

Liabilities / assets41.1%
Debt / equity0.00x
Current ratio6.11x
Interest coverage11.66x

Cash quality & payout

Operating cash flow / net income1.55x
Accruals ratio-1.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$19.61M$17.87M$15.11M$13.78M$12.46M$9.65M$8.75M$7.92M
R&D expense$154,000$118,000$49,000$20,000$29,000$107,000$94,000$50,000
SG&A expense$3.91M$4.64M$3.19M$8.44M$5.45M$6.53M$5.87M$4.20M
Operating income$4.65M$1.74M-$119,000-$2.55M-$189,000-$2.73M-$808,000-$934,000
Interest expense$1,000$3,000$7,000$308,000$586,000$594,000$592,000$966,000
Pretax income$4.97M$2.02M—-$4.68M-$638,000-$3.15M——
Income tax$332,000$42,000—$106,000$0$0$0—
Net income$4.64M$1.97M$201,000-$4.79M-$638,000-$3.15M-$1.17M-$1.99M
EPS (basic)0.130.060.01—-0.02-0.11-0.04—
EPS (diluted)0.120.050.01—-0.02-0.11-0.04—
Weighted avg. shares (diluted)38.08M36.43M35.55M—27.89M27.66M27.58M—
Balance sheet
Cash & equivalents$48.68M$41.25M$40.18M$36.79M$21.95M$18.70M$22.68M$26.63M
Current assets$80.95M$72.50M$66.88M$67.04M$46.06M$40.79M$42.98M$44.12M
Total assets$83.54M$75.75M$71.82M$70.55M$49.26M$44.88M$46.40M$44.95M
Current liabilities$13.24M$12.39M$9.59M$10.52M$9.81M$8.41M$8.37M$6.92M
Long-term debt————$19.38M$19.36M$19.35M$19.34M
Total debt————$19.38M$19.36M$19.35M$19.34M
Total liabilities$34.35M$33.31M$34.15M$35.08M$53.75M$52.34M$52.28M$50.82M
Shareholders' equity$49.19M$42.44M$37.67M$35.47M-$4.49M-$7.46M-$5.88M-$5.87M
Net debt————-$2.57M$659,000-$3.32M-$7.30M
Shares outstanding35.22M35.03M34.54M34.16M28.06M27.73M27.59M27.53M
Cash flow statement
Operating cash flow$6.68M$50,000$2.38M-$5.96M$1.49M-$3.69M-$4.32M-$1.47M
Financing cash flow$753,000$1.02M$1.01M$20.80M$1.75M-$284,000$359,000-$12.21M
Stock-based compensation$1.35M$1.77M$990,000$2.52M$2.22M$1.49M$798,000$1.12M

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.